statement
At 52 weeks, the apnea-hypopnea index fell by an average 19.1 events per hour with Foundayo versus 3.6 with placebo.
A statement by Lilly. Statements are as reported by the cited publishers — not verified by DecisionGateway.
At 52 weeks, the apnea-hypopnea index fell by an average 19.1 events per hour with Foundayo versus 3.6 with placebo.
Discussion
Related claims
Foundayo, its once-daily oral GLP-1 pill orforglipron, met the primary endpoint in the Phase 3 ATTAIN-OSA trial for adults with obesity and moderate-to-severe obstructive sleep apnea.Eli Lilly · statementThe high placebo response rate is because all patients received 600mg high dose for 16 weeks in Period 1, not because of a large placebo effect; 75% of the placebo group maintained ACR20 through week 28.현대차증권 제약/바이오/의료기기 김현석 · statementThis widens Foundayo's commercial lane beyond weight loss alone.MY READ · predictionIf regulators accept the sleep-apnea data, Lilly gains a second disease-specific use for an oral obesity drug and a cleaner pitch to patients who do not want injections.MY READ · predictionFour-week averages were between 2% and 2.3%.post author · statementThe October NFP came in extremely weak last month.post author · statement